<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05029635</url>
  </required_header>
  <id_info>
    <org_study_id>2020-523-00CH1</org_study_id>
    <nct_id>NCT05029635</nct_id>
  </id_info>
  <brief_title>Phase III Study on HMPL-523 for Treatment of ITP</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HMPL-523 in Treatment of Primary Immune Thrombocytopenia (ITP) in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hutchison Medipharma Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hutchison Medipharma Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double blinded, placebo-controlled phase III clinical trial in adult&#xD;
      patients with immune thrombocytopenia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximate 177 patients will be enrolled in study (HMPL-523 2:1 vs Placebo) .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the durable response rate in the primary study</measure>
    <time_frame>treatment period Week14-Week24</time_frame>
    <description>Platelet count ≥50×10^9 /L on at least 4 of 6 scheduled visits of Week14-Week24 in the primary study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the overall response rate in the primary study</measure>
    <time_frame>treatment period Week1-Week24 in the primary study</time_frame>
    <description>At least one platelet count ≥50×10^9 /L (except that induced by the rescue therapy) in the 24-week double-blind treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment emergent adverse events</measure>
    <time_frame>treatment period Week1-Week24 in the primary study</time_frame>
    <description>Adverse events classified according to NCI CTCAE version 5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration at steady state 2 hours post dose (C2h,ss)</measure>
    <time_frame>treatment period Week1-Week24 in the primary study</time_frame>
    <description>Plasma concentration of HMPL-523 and its main metabolites at steady state 2 hours post dose (C2h,ss) will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration at steady state 2 hours post dose (C4h,ss)</measure>
    <time_frame>treatment period Week1-Week24 in the primary study</time_frame>
    <description>Plasma concentration of HMPL-523 and its main metabolites at steady state 4 hours post dose (C4h,ss) will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration at steady-state trough concentration (Cmin,ss)</measure>
    <time_frame>treatment period Week1-Week24 in the primary study</time_frame>
    <description>Plasma concentration of HMPL-523 and its main metabolites at steady-state trough concentration (Cmin,ss) will be determined.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">177</enrollment>
  <condition>Immune Thrombocytopenia (ITP)</condition>
  <arm_group>
    <arm_group_label>treatment arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eligible subjects will be treated with planned dose of 300 mg HMPL-523 once daily for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: Placebo HMPL-523 matching placebo will be oral administrated once daily for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HMPL-523</intervention_name>
    <description>HMPL-523 will be oral administrated once daily for 24 weeks</description>
    <arm_group_label>treatment arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>HMPL-523 matching placebo will be oral administrated once daily for 24 weeks .</description>
    <arm_group_label>placebo arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Voluntary signature of written informed consent form;&#xD;
&#xD;
          2. Male or female aged 18~75 years;&#xD;
&#xD;
          3. Performance Status score [Eastern Cooperative Oncology Group (ECOG) score] 0~1;&#xD;
&#xD;
          4. Having been diagnosed as ITP prior to randomization, and duration of disease is more&#xD;
             than 6 months;&#xD;
&#xD;
          5. Intolerance or insufficient response, or recurrence after at least one anti-ITP&#xD;
             standard drug therapy;&#xD;
&#xD;
          6. Patients must have a history of response to previous ITP therapy;&#xD;
&#xD;
          7. One combined anti-ITP therapy is allowed in this study, however, the following&#xD;
             criteria need to be met:&#xD;
&#xD;
               1. The dose of glucocorticoid has been stable for 4 weeks prior to randomization&#xD;
                  (&lt;20 mg Prednisone equivalent);&#xD;
&#xD;
               2. The dose of Danazol has been stable for 3 months prior to randomization;&#xD;
&#xD;
               3. The dose of immunosuppressant (only including Azathioprine, Ciclosporin A,&#xD;
                  Mycophenolate mofetil) has been stable for 3 months prior to randomization.&#xD;
&#xD;
          8. The condition is relatively stable; WHO bleeding scale grade is 0-1; no emergency&#xD;
             treatment is expected within 2 weeks as judged by investigators.&#xD;
&#xD;
          9. The laboratory examinations need to meet the following conditions (no treatment for&#xD;
             this abnormal variable is given within one week prior to blood collection):&#xD;
&#xD;
               1. Platelet count &lt;30×109 /L for twice (at an interval of more than 24 hours) in&#xD;
                  screening period (except that induced by rescue therapy);&#xD;
&#xD;
               2. Hemoglobin ≥100 g/L, neutrophil count &gt;1.5×109/L;&#xD;
&#xD;
               3. Total bilirubin (TBIL), alanine aminotransferase (ALT) and aspartate&#xD;
                  aminotransferase (AST) ≤1.5×upper limit of normal (ULN);&#xD;
&#xD;
               4. Serum creatinine concentration ≤1.5×ULN and creatinine clearance ≥50 mL/min;&#xD;
&#xD;
               5. Serum amylase and lipase ≤1.5×ULN;&#xD;
&#xD;
               6. International normalized ratio (INR), activated partial thromboplastin time&#xD;
                  (APTT) not exceeding 20% of normal range.&#xD;
&#xD;
         10. Male or female patients of childbearing potential must agree to use effective&#xD;
             contraceptive methods during the study and within 90 days after last dose of study&#xD;
             drug, e.g., double barrier contraceptive method, condom, oral or injectable&#xD;
             contraceptives, intrauterine device, etc. Postmenopausal women (&gt;50 years old and no&#xD;
             menses for &gt;1 year) and surgically sterilized women are not subject to this condition.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence on the presence of secondary causes of immune thrombocytopenia (e.g.,&#xD;
             previous history of untreated helicobacter pylori infection, leukemia, lymphoma,&#xD;
             common variable immunodeficiency, systemic lupus erythematosus and autoimmune thyroid&#xD;
             disorder), or drug therapy (e.g., heparin, quinine, antimicrobial drugs,&#xD;
             anticonvulsants), or multiple immune hemocytopenia in the participants, e.g., Evan's&#xD;
             syndrome;&#xD;
&#xD;
          2. Clinically serious hemorrhage requiring immediate adjustment of platelet (e.g.,&#xD;
             hypermenorrhea with significantly decreased hemoglobin);&#xD;
&#xD;
          3. Clinically symptomatic gastrointestinal hemorrhage within 6 months prior to screening&#xD;
             visit (e.g., haematemesis, tarry stool, however, the positive occult blood test&#xD;
             without any sign or symptom of gastrointestinal hemorrhage will not be considered as&#xD;
             &quot;clinically symptomatic&quot;, or hemorrhoids hemorrhage is one exception);&#xD;
&#xD;
          4. known history of vital organ transplantation or hematopoietic stem cell / bone marrow&#xD;
             transplantation;&#xD;
&#xD;
          5. Has received live vaccine within 8 weeks prior to Day 1 (baseline visit); or plan for&#xD;
             immunization with live vaccine during the study;&#xD;
&#xD;
          6. Splenectomy within 12 weeks prior to randomization;&#xD;
&#xD;
          7. Major surgery within 4 weeks prior to the randomization, or plan for major elective&#xD;
             surgery during the study;&#xD;
&#xD;
          8. Previous history of malignant tumors (except for the basal cell carcinoma of skin or&#xD;
             cervical carcinoma in situ that have been cured);&#xD;
&#xD;
          9. History of important arterial / venous embolic disease;&#xD;
&#xD;
         10. Intracranial hemorrhage within 6 months before screening visit;&#xD;
&#xD;
         11. History of serious cardiovascular disease (e.g., grade III/IV congestive heart&#xD;
             failure, arrhythmia or angina pectoris requiring drug therapy, unstable angina&#xD;
             pectoris, intracoronary stent implantation, angioplasty or coronary artery bypass&#xD;
             grafting, or QTc ≥450 ms);&#xD;
&#xD;
         12. Hypertension that can not be controlled with drugs (systolic blood pressure ≥140 mmHg&#xD;
             or diastolic blood pressure ≥90 mmHg);&#xD;
&#xD;
         13. Previous history of serious gastrointestinal disease, such as dysphagia, active&#xD;
             gastric ulcer, inability to take drugs orally or absorption disorder for oral drugs;&#xD;
&#xD;
         14. Human immunodeficiency virus (HIV) infection, or hepatitis B (in case of positive&#xD;
             HBsAg or HBcAb, positive HBV DNA needs to be determined), or hepatitis C (positive HCV&#xD;
             RNA), or liver cirrhosis;&#xD;
&#xD;
         15. Significant active infection that is not controlled clinically (e.g., sepsis,&#xD;
             pneumonia or abscess), or serious infection within 6 weeks prior to randomization&#xD;
             (leading to hospitalization or requiring treatment with antibiotic injections);&#xD;
&#xD;
         16. Has received rescue therapy for ITP within 2 weeks prior to randomization;&#xD;
&#xD;
         17. Has received the treatment for the objective of increasing platelet within 4 weeks&#xD;
             prior to randomization (including but not limited to glucocorticoid, thrombopoietin,&#xD;
             thrombopoietin receptor agonist, Cyclosporine A, Mycophenolate mofetil, etc.), except&#xD;
             those meeting the inclusion criterion 7;&#xD;
&#xD;
         18. Having received Rituximab within 14 weeks prior to randomization;&#xD;
&#xD;
         19. Having received traditional Chinese medicine within 1 week prior to randomization;&#xD;
&#xD;
         20. Requiring long-term/continuous use of the drugs that may affect platelet function&#xD;
             [including but not limited to aspirin, Clopidogrel, ticagrelor, NSAIDs, etc.], or&#xD;
             anticoagulants;&#xD;
&#xD;
         21. Intake of potent CYP3A inhibitor or inducer, as well as sensitive or narrow&#xD;
             therapeutic window substrates of CYP3A, CYP1A2 or CYP2B6 two weeks (three weeks for&#xD;
             Hypericum perforatum) or 5 half-lives prior to randomization (whichever is longer);&#xD;
&#xD;
         22. Having participated in the clinical study for drugs or invasive medical device 4 weeks&#xD;
             prior to randomization (or within 5 half-lives of the study drug prior to&#xD;
             randomization, whichever is longer);&#xD;
&#xD;
         23. Having received spleen tyrosine kinase Syk inhibitor (e.g., Fostamatinib) previously;&#xD;
&#xD;
         24. Known allergy to the active ingredient or excipient of study drug;&#xD;
&#xD;
         25. Presence of serious psychological or mental disorder;&#xD;
&#xD;
         26. Alcoholic or drug abuser;&#xD;
&#xD;
         27. Female patients in pregnancy or breast feeding;&#xD;
&#xD;
         28. Being unsuitable to participate in this study, as considered by investigators.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hongyan Yin</last_name>
    <phone>201-20671823</phone>
    <email>hongyany@hutch-med.com</email>
  </overall_contact>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 8, 2021</study_first_submitted>
  <study_first_submitted_qc>August 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2021</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

